News headlines about NovoCure Limited (NASDAQ:NVCR) have trended somewhat positive on Friday, according to Accern. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NovoCure Limited earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 45.1227586183978 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted Accern’s scoring:
- NovoCure Limited (NVCR) registers a price change of 4.10% while Galmed Pharmaceuticals Ltd. (GLMD) finishes with … – Stocks Gallery (stocksgallery.com)
- A Side-by-side Analysis of NovoCure Limited (NVCR) and Accuray Incorporated (ARAY) – StockNewsGazette (stocknewsgazette.com)
- Changes in Signals Identified: NovoCure Limited (NVCR), Cloud Peak Energy Inc. (CLD) – AllStockNews (allstocknews.com)
- NovoCure Limited (NVCR) Insider bought 354780 Shares – Economic News (economicsandmoney.com)
- Stocks; In Focus: Majesco, Corcept Therapeutics, MiMedx And Supernus – Investing.com (investing.com)
Several research firms have recently issued reports on NVCR. Wells Fargo & Company upgraded shares of NovoCure Limited from a “market perform” rating to an “outperform” rating and set a $15.00 target price for the company in a report on Wednesday, May 24th. Deutsche Bank AG lifted their target price on shares of NovoCure Limited from $10.00 to $11.00 and gave the company a “hold” rating in a report on Friday, April 28th. Wedbush reiterated an “outperform” rating and set a $20.00 target price on shares of NovoCure Limited in a report on Thursday, April 27th. Zacks Investment Research lowered shares of NovoCure Limited from a “buy” rating to a “hold” rating in a report on Saturday, April 22nd. Finally, BidaskClub upgraded shares of NovoCure Limited from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. NovoCure Limited currently has a consensus rating of “Buy” and an average target price of $19.29.
NovoCure Limited (NASDAQ NVCR) traded up 0.26% during trading on Friday, hitting $19.30. 430,917 shares of the stock traded hands. NovoCure Limited has a 12 month low of $5.95 and a 12 month high of $21.75. The firm’s market cap is $1.72 billion. The firm has a 50-day moving average price of $18.89 and a 200 day moving average price of $12.57.
NovoCure Limited (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.01. NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. The business had revenue of $38.38 million for the quarter, compared to the consensus estimate of $42.20 million. On average, equities analysts forecast that NovoCure Limited will post ($0.75) EPS for the current fiscal year.
In other news, insider Yoram Palti sold 4,000 shares of the stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $13.15, for a total transaction of $52,600.00. Following the transaction, the insider now directly owns 29,256 shares in the company, valued at $384,716.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Pomona Capital Vii Fund Invest sold 1,072,532 shares of the stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $17.35, for a total transaction of $18,608,430.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,253,522 shares of company stock worth $38,336,772. Insiders own 16.70% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “NovoCure Limited (NVCR) Receives Media Sentiment Score of 0.10” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/18/novocure-limited-nvcr-receives-media-sentiment-score-of-0-10.html.
NovoCure Limited Company Profile
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
What are top analysts saying about NovoCure Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NovoCure Limited and related companies.